Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG) following the company's first full quarter of ZUNVEYL® commercialization. This period saw significant early adoption in the U.S. long-term care market and a key regulatory milestone in China. ZUNVEYL has been ordered in over 300 long-term care facilities with 65% placing repeat orders. Additionally, Alpha Cognition secured its first national Medicare Part D contract, enhancing patient access. For more details, visit newsfilecorp.com/release/177020.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262742) on August 15, 2025, and is solely responsible for the information contained therein.